What is a Growth Hormone Secretagogue?
A Growth Hormone Secretagogue (GHS) is a compound that stimulates the secretion of growth hormone (GH) from the pituitary gland. The term encompasses both endogenous signalling molecules and synthetic compounds designed to activate the GH secretagogue receptor pathway. In the context of synthetic peptide research, GHS compounds are used as reference tools for studying somatotropic axis signalling in controlled in-vitro and preclinical experimental models.
The Ghrelin Receptor (GHSR-1a)
The primary receptor target for GHS peptide compounds is the Growth Hormone Secretagogue Receptor type 1a (GHSR-1a), commonly referred to as the ghrelin receptor. GHSR-1a is a G protein-coupled receptor expressed predominantly in the pituitary gland and hypothalamus, with additional expression in peripheral tissues including the stomach, heart, and adipose tissue.
The endogenous ligand for GHSR-1a is ghrelin — a 28-amino acid acylated peptide produced primarily in the stomach. Ghrelin was identified in 1999 as the endogenous ligand for the previously orphaned GHS receptor, confirming the existence of a dedicated GH-stimulating signalling pathway distinct from the GHRH pathway.
GHS Research Compounds
Peptide GHS Compounds
Synthetic peptide GHS compounds are structurally related to ghrelin or designed to mimic its receptor binding characteristics. They vary in selectivity, potency, and duration of receptor engagement.
Ipamorelin: A pentapeptide GHS with high selectivity for GHSR-1a. Minimal off-target activity at other receptor classes makes it a preferred reference compound for isolating GHSR-1a-mediated pathway responses in research models.
GHRP-6 and GHRP-2: Earlier-generation hexapeptide GHS compounds with broader receptor activity profiles, including significant activity at cortisol and prolactin pathway receptors — limiting their utility as selective research tools.
GHRH Analogs vs. GHS Peptides
It is important to distinguish GHS compounds (which act via the ghrelin receptor) from GHRH analogs (which act via the GHRH receptor):
GHRH analogs (e.g. CJC-1295, Tesamorelin): Act via the GHRH receptor on pituitary somatotrophs to stimulate GH release through a different mechanistic pathway
GHS peptides (e.g. Ipamorelin): Act via GHSR-1a; can be used in combination with GHRH analogs in research models examining additive or synergistic somatotropic pathway effects
Selectivity in GHS Research
Selectivity is a critical consideration when designing GHS research experiments. Less selective compounds that activate multiple receptor pathways simultaneously make it difficult to attribute observed effects to a specific receptor interaction. High-selectivity compounds like Ipamorelin allow researchers to study GHSR-1a-mediated signalling with greater confidence in the specificity of the experimental model.
Designing GHS Research Models
When applying GHS peptides in in-vitro research:
Select compounds based on receptor selectivity requirements for the experimental question
Consider whether the research goal requires acute pulsatile stimulation (short-acting compound) or sustained receptor engagement (longer-acting compound)
Use appropriate controls including vehicle controls and receptor antagonist controls where available
Account for potential receptor desensitisation in extended exposure models
